Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Discovery & Development Clinical Trials

Positive Results in Alzheimer’s Trial

Eisai and Biogen’s experimental BAN2401 drug – a humanized mAb designed as an anti beta-amyloid therapy) hit targets in a Phase II trial involving patients with early Alzheimer’s disease, slowing clinical decline and reducing amyloid beta accumulated in the brain measured using amyloid positron emission tomography (1). The drug was tested at various doses, with all showing a reduction in amyloid plaques, but a slowing of cognitive decline was only seen with the highest dose (10 mg/kg biweekly) – patients on this dose declined 30 percent slower compared with placebo.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login if you already created an account

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login as a Guest or via Social Media

About the Author

Stephanie Sutton

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent seven years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register